Macular Holes in Tractional Retinal Detachments Secondary to Diabetic Retinopathy.

Autor:	Sharma N; Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA., Akotoye C; Case Western Reserve University School of Medicine, Cleveland, OH, USA., Perkins S; Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA., Sastry R; Creighton University School of Medicine, Omaha, NE, USA., Wu AK; Case Western Reserve University School of Medicine, Cleveland, OH, USA., Singh RP; Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.; Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.; Cleveland Clinic Martin Hospitals, Cleveland Clinic Florida, Stuart, FL, USA., Franklin AJ; Infirmary Health's Diagnostic & Medical Clinic, Mobile, AL, USA., Rachitskaya A; Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Jazyk:	angličtina
Zdroj:	Journal of vitreoretinal diseases [J Vitreoretin Dis] 2024 Mar 19; Vol. 8 (3), pp. 317-324. Date of Electronic Publication: 2024 Mar 19 (Print Publication: 2024).
DOI:	10.1177/24741264241239753
Abstrakt:	Purpose: To characterize the visual outcomes and rate of macular hole (MH) closure with tractional retinal detachment (TRD) and proliferative diabetic retinopathy (PDR). Methods: Visit data of patients who had pars plana vitrectomy were retrospectively reviewed; patient demographics, other procedure(s), the MH closure rate, and visual outcomes were also collected. Paired t , Fisher exact, and Mann-Whitney U tests were performed. Results: Ten patients (10 eyes) developed a TRD MH; 3 distinct MH presentations were identified. At the 3-month follow-up, 90% of MHs remained closed without the need for further reoperation (n = 6, type 1 closure; n = 3, type 2 closure). All MHs were closed 12 months after the initial surgery, with 1 eye requiring a single reoperation. The mean visual acuity (VA) at baseline and at 12 months was 20/235 and 20/138, respectively. Conclusions: MHs in the setting of fibrovascular proliferation resulting from PDR present with varied morphology. There is a high rate of MH closure and a trend toward improved VA. Competing Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Singh reported personal fees from Genentech/Roche, personal fees from Alcon/Novartis, grants from Apellis and Graybug, personal fees from Zeiss, personal fees from Bausch + Lomb, personal fees from Ophthea, and personal fees from Regeneron Pharmaceuticals, Inc. Dr. Franklin reported consulting fees from Alcon and is the founder of ForwardVue Pharma. Dr. Rachitskaya reported consulting fees from Alcon, Zeiss, Novartis, and Genentech; speaker fees from Regeneron; and research fees from Genentech, AGCT, Novartis, and Apellis. None of the other authors reported disclosures. (© The Author(s) 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu